GSK3B and cancer: Immunohistochemically, nuclear localization of β-catenin in the cancer cells was frequently observed in tumors treated with GSK-3β inhibitors, whereas weak cytoplasmic expression was found in control tumors (Figure 6C; Supplementary Figure S9).